SMITHS FALLS, ON, Sept. 17, 2019 /CNW/ - Canopy Growth
Corporation (TSX:WEED) (NYSE: CGC) ("Canopy Growth" or "the
Corporation") today announced that all of management's nominees
listed in its August 8, 2019
management information circular were elected as directors of the
Corporation at Canopy Growth's September 17,
2019 annual general meeting of shareholders (the "Annual
Meeting"). The detailed results of the vote for the election of
directors held at the Annual Meeting are set out below.
Name of
Nominee
|
Votes cast
FOR
|
% votes cast
FOR
|
Votes
WITHHELD
|
% votes
WITHHELD
|
John K.
Bell
|
144,593,217
|
97.00
|
4,464,630
|
3.00
|
Robert
Hanson
|
145,983,248
|
97.94
|
3,074,600
|
2.06
|
David
Klein
|
146,276,600
|
98.13
|
2,781,249
|
1.87
|
William
Newlands
|
145,129,921
|
97.36
|
3,927,928
|
2.64
|
Judy A.
Schmeling
|
146,410,051
|
98.22
|
2,647,797
|
1.78
|
Peter
Stringham
|
144,141,942
|
96.70
|
4,915,907
|
3.30
|
Mark
Zekulin
|
146,286,192
|
98.14
|
2,771,657
|
1.86
|
At the Annual Meeting, Canopy Growth shareholders also approved
the appointment of KPMG LLP as the Corporation's auditors for the
ensuing year and authorized the board of directors to fix its
remuneration.
About Canopy Growth Corporation
Canopy Growth
(TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp
and cannabis device company, offering distinct brands and curated
cannabis varieties in dried, oil and Softgel capsule forms, as well
as medical devices through Canopy Growth's subsidiary, Storz &
Bickel GMbH & Co. KG. From product and process innovation to
market execution, Canopy Growth is driven by a passion for
leadership and a commitment to building a world-class cannabis
company one product, site and country at a time. Canopy Growth has
operations in over a dozen countries across five continents.
Canopy Growth's medical division, Spectrum Therapeutics is
proudly dedicated to educating healthcare practitioners, conducting
robust clinical research, and furthering the public's understanding
of cannabis, and has devoted millions of dollars toward cutting
edge, commercializable research and IP development. Spectrum
Therapeutics sells a range of full-spectrum products using its
colour-coded classification Spectrum system as well as single
cannabinoid Dronabinol under the brand Bionorica Ethics.
Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo
Smoke banners. Tweed is a globally recognized cannabis brand which
has built a large and loyal following by focusing on quality
products and meaningful customer relationships.
From our historic public listing on the Toronto Stock Exchange
and New York Stock Exchange to our continued international
expansion, pride in advancing shareholder value through leadership
is engrained in all we do at Canopy Growth. Canopy Growth has
established partnerships with leading sector names including
cannabis icons Snoop Dogg and Seth
Rogen, breeding legends DNA Genetics and Green House Seeds,
and Fortune 500 alcohol leader Constellation Brands, to name but a
few. Canopy Growth operates eleven licensed cannabis production
sites with over 4.7 million square feet of production capacity,
including over one million square feet of GMP certified production
space. For more information visit www.canopygrowth.com
View original
content:http://www.prnewswire.com/news-releases/canopy-growth-announces-election-of-board-of-directors-300920284.html
SOURCE Canopy Growth Corporation